Quantitative phosphoproteomics of transforming growth factor-β signaling in colon cancer cells

Proteomics

Volumn 11, Issue 16, 2011, Pages 3390-3401

  Ali, Naveid A ^a   Molloy, Mark P ^a  

^a MACQUARIE UNIVERSITY   (Australia)

Author keywords

Cancer; Cell biology; Mass spectrometry; Phosphorylation; Smad4; Transforming growth factor

Indexed keywords

AMINO ACID; CASEIN; CYCLIN DEPENDENT KINASE; HEPATOMA DERIVED GROWTH FACTOR; MEMBRANE PROTEIN; PHOSPHOPEPTIDE; PROGRAMMED CELL DEATH PROTEIN 4; SMAD4 PROTEIN; STABLE ISOTOPE; TITANIUM DIOXIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CULTURE; CELL DIVISION; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; ISOTOPE LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; COLONIC NEOPLASMS; HUMANS; ISOTOPE LABELING; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEOME; PROTEOMICS; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; TITANIUM; TNF RECEPTOR-ASSOCIATED FACTOR 2; TRANSFORMING GROWTH FACTOR BETA;

EID: 79960815170     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201100036     Document Type: Article

References (59)

1. Massague, J., Wotton, D., Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 2000, 19, 1745-1754.
2. Wakefield, L. M., Roberts, A. B., TGF-beta signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 2002, 12, 22-29.
3. Attisano, L., Wrana, J. L., Signal transduction by the TGF-beta superfamily. Science 2002, 296, 1646-1647.
4. Datto, M. B., Li, Y., Panus, J. F., Howe, D. J. et al., Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA 1995, 92, 5545-5549.
5. Pietenpol, J. A., Holt, J. T., Stein, R. W., Moses, H. L., Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. Proc. Natl. Acad. Sci. USA 1990, 87, 3758-3762.
6. Reynisdottir, I., Massague, J., The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 1997, 11, 492-503.
7. Liu, T., Feng, X. H., Regulation of TGF-beta signalling by protein phosphatases. Biochem. J. 2010, 430, 191-198.
8. Wrighton, K. H., Lin, X., Feng, X. H., Phospho-control of TGF-beta superfamily signaling. Cell. Res. 2009, 19, 8-20.
9. Akhurst, R. J., Derynck, R., TGF-beta signaling in cancer - a double-edged sword. Trends Cell. Biol. 2001, 11, S44-S51.
10. Derynck, R., Zhang, Y. E., Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425, 577-584.
11. Duda, D. G., Sunamura, M., Lefter, L. P., Furukawa, T. et al., Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene 2003, 22, 6857-6864.
12. Galliher, A. J., Schiemann, W. P., Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res. 2007, 67, 3752-3758.
13. Yu, L., Hebert, M. C., Zhang, Y. E., TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 2002, 21, 3749-3759.
14. Runyan, C. E., Poncelet, A. C., Schnaper, H. W., TGF-beta receptor-binding proteins: complex interactions. Cell Signal. 2006, 18, 2077-2088.
15. Yu, L., Hebert, M. C., Zhang, Y. E., TGF-[beta] receptor-activated p38 MAP kinase mediates Smad-independent TGF-[beta] responses. EMBO J. 2002, 21, 3749-3759.
16. Bierie, B., Moses, H. L., TGF-beta and cancer. Cytokine Growth Factor Rev. 2006, 17, 29-40.
17. Levy, L., Hill, C. S., Smad4 dependency defines two classes of transforming growth factor beta (TGF-beta) target genes and distinguishes TGF-beta-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol. Cell. Biol. 2005, 25, 8108-8125.
18. Schwarte-Waldhoff, I., Klein, S., Blass-Kampmann, S., Hintelmann, A. et al., DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression. Oncogene 1999, 18, 3152-3158.
19. Ali, N. A., McKay, M. J., Molloy, M. P., Proteomics of Smad4 regulated transforming growth factor-beta signalling in colon cancer cells. Mol. Biosyst. 2010, 6, 2332-2338.
20. Thingholm, T. E., Jorgensen, T. J., Jensen, O. N., Larsen, M. R., Highly selective enrichment of phosphorylated peptides using titanium dioxide. Nat. Protoc. 2006, 1, 1929-1935.
21. Shilov, I. V., Seymour, S. L., Patel, A. A., Loboda, A. et al., The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol. Cell. Proteomics 2007, 6, 1638-1655.
22. Li, T., Li, W., Lu, J., Liu, H. et al., SH2D4A regulates cell proliferation via the ERalpha/PLC-gamma/PKC pathway. BMB Rep. 2009, 42, 516-522.
23. Miller, M. L., Blom, N., Kinase-specific prediction of protein phosphorylation sites. Methods Mol. Biol. 2009, 527, 299-310, x.
24. Ziolkowski, P., Gamian, E., Osiecka, B., Zougman, A., Wisniewski, J. R., Immunohistochemical and proteomic evaluation of nuclear ubiquitous casein and cyclin-dependent kinases substrate in invasive ductal carcinoma of the breast. J. Biomed. Biotechnol. 2009, 2009, 919645.
25. Wisniewski, J. R., Zougman, A., Kruger, S., Ziolkowski, P. et al., Constitutive and dynamic phosphorylation and acetylation sites on NUCKS, a hypermodified nuclear protein, studied by quantitative proteomics. Proteins 2008, 73, 710-718.
26. Chi, Y., Welcker, M., Hizli, A. A., Posakony, J. J. et al., Identification of CDK2 substrates in human cell lysates. Genome Biol. 2008, 9, R149.
27. Jin, H., Kim, T. H., Hwang, S. K., Chang, S. H. et al., Aerosol delivery of urocanic acid-modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice. Mol. Cancer Ther. 2006, 5, 1041-1049.
28. Matsuhashi, S., Narisawa, Y., Ozaki, I., Mizuta, T., Expression patterns of programmed cell death 4 protein in normal human skin and some representative skin lesions. Exp. Dermatol. 2007, 16, 179-184.
29. Mudduluru, G., Medved, F., Grobholz, R., Jost, C. et al., Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer 2007, 110, 1697-1707.
30. Chen, L., Giorgianni, F., Beranova-Giorgianni, S., Characterization of the phosphoproteome in LNCaP prostate cancer cells by in-gel isoelectric focusing and tandem mass spectrometry. J. Proteome Res. 2010, 9, 174-178.
31. Palamarchuk, A., Efanov, A., Maximov, V., Aqeilan, R. I. et al., Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Res. 2005, 65, 11282-11286.
32. Dorrello, N. V., Peschiaroli, A., Guardavaccaro, D., Colburn, N. H. et al., S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006, 314, 467-471.
33. Zhang, H., Ozaki, I., Mizuta, T., Hamajima, H. et al., Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene 2006, 25, 6101-6112.
34. Fu, C. A., Shen, M., Huang, B. C., Lasaga, J. et al., TNIK, a novel member of the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and regulates the cytoskeleton. J. Biol. Chem. 1999, 274, 30729-30737.
35. Oppermann, F. S., Gnad, F., Olsen, J. V., Hornberger, R. et al., Large-scale proteomics analysis of the human kinome. Mol. Cell. Proteomics 2009, 8, 1751-1764.
36. Mahmoudi, T., Li, V. S., Ng, S. S., Taouatas, N. et al., The kinase TNIK is an essential activator of Wnt target genes. EMBO J. 2009, 28, 3329-3340.
37. Shitashige, M., Satow, R., Jigami, T., Aoki, K. et al., Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. Cancer Res. 2010, 70, 5024-5033.
38. Parker, L. L., Piwnica-Worms, H., Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992, 257, 1955-1957.
39. Fattaey, A., Booher, R. N., Myt1: a Wee1-type kinase that phosphorylates Cdc2 on residue Thr14. Prog. Cell Cycle Res. 1997, 3, 233-240.
40. Mueller, P. R., Coleman, T. R., Kumagai, A., Dunphy, W. G., Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 1995, 270, 86-90.
41. Morgan, D. O., Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell. Dev. Biol. 1997, 13, 261-291.
42. Sherr, C. J., Roberts, J. M., Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004, 18, 2699-2711.
43. Furuno, N., den Elzen, N., Pines, J., Human cyclin A is required for mitosis until mid prophase. J. Cell. Biol. 1999, 147, 295-306.
44. Riabowol, K., Draetta, G., Brizuela, L., Vandre, D., Beach, D., The cdc2 kinase is a nuclear protein that is essential for mitosis in mammalian cells. Cell 1989, 57, 393-401.
45. Ren, S., Rollins, B. J., Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell 2004, 117, 239-251.
46. Satyanarayana, A., Kaldis, P., Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009, 28, 2925-2939.
47. Iavarone, A., Massague, J., Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Nature 1997, 387, 417-422.
48. Wang, W., Ungermannova, D., Jin, J., Harper, J. W., Liu, X., Negative regulation of SCFSkp2 ubiquitin ligase by TGF-beta signaling. Oncogene 2004, 23, 1064-1075.
49. Nakamura, H., Izumoto, Y., Kambe, H., Kuroda, T. et al., Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J. Biol. Chem. 1994, 269, 25143-25149.
50. Chang, K. C., Tai, M. H., Lin, J. W., Wang, C. C. et al., Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int. J. Cancer 2007, 121, 1059-1065.
51. Yoshida, K., Tomita, Y., Okuda, Y., Yamamoto, S. et al., Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann. Surg. Oncol. 2006, 13, 159-167.
52. Ren, H., Tang, X., Lee, J. J., Feng, L. et al., Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J. Clin. Oncol. 2004, 22, 3230-3237.
53. Uyama, H., Tomita, Y., Nakamura, H., Nakamori, S. et al., Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin. Cancer Res. 2006, 12, 6043-6048.
54. Thakar, K., Krocher, T., Savant, S., Gollnast, D. et al., Secretion of hepatoma-derived growth factor is regulated by N-terminal processing. Biol. Chem. 2010, 391, 1401-1410.
55. Everett, A. D., Stoops, T., McNamara, C. A., Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J. Biol. Chem. 2001, 276, 37564-37568.
56. Kishima, Y., Yamamoto, H., Izumoto, Y., Yoshida, K. et al., Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J. Biol. Chem. 2002, 277, 10315-10322.
57. Tsang, T. Y., Tang, W. Y., Tsang, W. P., Co, N. N. et al., Downregulation of hepatoma-derived growth factor activates the Bad-mediated apoptotic pathway in human cancer cells. Apoptosis 2008, 13, 1135-1147.
58. Yang, J., Everett, A. D., Hepatoma-derived growth factor represses SET and MYND domain containing 1 gene expression through interaction with C-terminal binding protein. J. Mol. Biol. 2009, 386, 938-950.
59. Liu, F., Smad3 phosphorylation by cyclin-dependent kinases. Cytokine Growth Factor Rev. 2006, 17, 9-17.